Bardoxolone methyl

Drug Profile

Bardoxolone methyl

Alternative Names: Bard - Reata Pharmaceuticals; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Kyowa Hakko Kirin; Reata Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules; Triterpenes
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Pulmonary arterial hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary arterial hypertension
  • Phase II/III Hereditary nephritis
  • Phase II Diabetic nephropathies
  • Discontinued Haematological malignancies; Malignant melanoma; Non-alcoholic steatohepatitis; Pancreatic cancer; Solid tumours; Viral hepatitis

Most Recent Events

  • 07 Mar 2017 Reata Pharamaceuticals plans a phase III trial for Pulmonary hypertension (NCT03068130)
  • 01 Feb 2017 Phase-II/III clinical trials in Hereditary nephritis in USA (PO) (NCT03019185)
  • 14 Nov 2016 Reata plans a phase II/III trial for Hereditary nephritis (Alport syndrome) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top